CDK4/6 inhibitors

Newly approved second generation of CDK4/6 inhibitors give hope to breast cancer patients

by Ilona Baraniak

Breast cancer is the most common type of cancer in women worldwide, with nearly 1.3 million new cases each year. It is the fifth most common cancer-related cause of death for women, and current predictions estimate a continuing rise of cases. CDK4/6 inhibitors provide promising options for the treatment of breast cancer. In this article, Ilona Baraniak provides insights into the area of newly approved second generation of CDK4/6 inhibitors.